Introduction {#s1}
============

When rifampin was first introduced, it held the promise of exceptional potency as an agent for treatment of *Mycobacterium tuberculosis* (the cause of tuberculosis \[TB\]). A series of randomized trials, most conducted 20--35 y ago, established that rifampin-containing regimens could achieve high cure rates with as few as 6 mo of therapy, even when given intermittently [@pmed.1000146-Fox1]. These trials ushered in the modern era of short-course chemotherapy and established the scientific rationale for the standardized regimens currently recommended by the World Health Organization (WHO) [@pmed.1000146-World1]. WHO recommends direct observation of all doses of rifampin to prevent rifampin resistance, which is associated with much worse treatment outcomes, especially when combined with isoniazid resistance as multi-drug resistance (MDR) [@pmed.1000146-Mitchison1],[@pmed.1000146-Caminero1]. This direct observation is facilitated by shorter duration of rifampin, and/or by intermittent dosing schedules.

However, the frequency of all forms of drug resistance has steadily increased in many countries over the last 20 y [@pmed.1000146-Espinal1]--[@pmed.1000146-WHO1]. The effectiveness of current empiric regimens in treating patients with unrecognized initial drug resistance of any form, including isoniazid mono-resistance, is unclear since this was not a focus of earlier trials. In particular, the adequacy of regimens that use rifampin only in the initial phase, or are intermittent throughout, may be questionable in settings with increasing drug resistance. In addition, the individual trials that form the scientific basis for current therapy were mostly small trials with limited power to evaluate the duration and intermittency of rifampin use. Hence meta-analysis of these trials can allow evaluation of factors that may have a small but clinically relevant effect on treatment outcomes.

In light of these uncertainties, we have conducted a systematic review of treatment regimens for active TB, to provide a basis for recommendations for revised treatment guidelines.

Review Questions {#s1a}
----------------

Our systematic review aimed to address two specific questions:

1.  What are the rates of treatment failure, relapse, and acquired drug resistance if rifampin is given only in the initial intensive phase (the first 1--2 mo), compared to longer duration?

2.  What are the rates of treatment failure, relapse, and acquired drug resistance with different dose administration schedules of therapy?

Methods {#s2}
=======

Search Strategy {#s2a}
---------------

We searched three electronic databases---PubMed, Embase, and the Cochrane CENTRAL database---for studies of treatment of active TB (i.e., disease). The search was restricted to randomized controlled trials published in English, French, and Spanish from 1965 up to June 2008. Our keywords included tuberculosis or TB, treatment or therapy, failure or relapse, or drug resistance. To identify additional relevant articles, we searched reference lists of identified original articles, recent systematic reviews [@pmed.1000146-Han1]--[@pmed.1000146-Gelband1], a review of all the British Medical Research Council trials [@pmed.1000146-Fox2], recent treatment guidelines [@pmed.1000146-American1],[@pmed.1000146-Public1], and texts [@pmed.1000146-Page1],[@pmed.1000146-Rieder1].

Study Selection {#s2b}
---------------

We included original reports of randomized controlled trials that reported treatment outcomes of bacteriologically confirmed failure and/or relapse. In selected trials, all patients had active pulmonary TB that was bacteriologically confirmed by AFB smear microscopy and/or mycobacterial culture, and had not been previously treated (i.e., were new cases). Treatment was standardized and included at least isoniazid and rifampin. We excluded trials or arms that included rifapentine or rifabutin therapy or non-drug therapy (e.g., immunotherapeutic vaccines). We also excluded trials, or arms, that involved once-weekly or mono-drug therapy, as these are now considered inadequate [@pmed.1000146-American1],[@pmed.1000146-Public1].

The selection of articles for review was done independently by two investigators in three stages: titles alone, followed by abstracts, and then full text articles. Decisions were compared and disagreements about study selection were resolved by consensus or by involving a third reviewer.

Data Extraction and Quality Assessment {#s2c}
--------------------------------------

We reviewed all selected studies using standardized forms to extract data about patient population and characteristics, treatment regimens, pretreatment drug-susceptibility testing, supervision of treatment, funding source, and number of patients who started treatment, defaulted or were otherwise lost, died, failed, or relapsed. Two reviewers extracted the data, with disagreements resolved by consensus.

We restricted the studies reviewed to randomized trials with bacteriologic confirmation of initial diagnosis, failure, and/or relapse---considered high-quality methods. Included studies were considered of high quality if less than 10% of patients refused therapy, dropped out, moved away, or were otherwise unaccounted for during therapy. In addition, randomized trials were considered high quality if they used an allocation concealment approach such as central randomization, numbered opaque sealed envelopes, sealed envelopes from a closed bag, numbered or coded bottles or containers, or if treatments were assigned by a central pharmacy.

Outcomes {#s2d}
--------

In line with internationally accepted definitions [@pmed.1000146-World3], treatment failure was defined as sputum smears and/or cultures that were consistently positive or requiring treatment at the end of therapy (if less than 5 mo) or after at least 5 mo of therapy. Relapse was defined as recurrence of positive smears and/or cultures that required therapy after completion of treatment with apparent cure. Initial drug resistance was defined as pretreatment resistance in patients without a history of previous treatment, and categorized as pan-sensitive, isoniazid resistant, streptomycin resistant, or resistant to both---termed poly-drug resistance. Patients with initial rifampin resistance, including MDR, were excluded from analysis, if identified in the published report. Acquired drug resistance was defined as new or additional resistance to one or more of the TB drugs received, among failures or relapses.

Data Synthesis and Analysis {#s2e}
---------------------------

We were interested in understanding the efficacy of different regimens in preventing failure, relapse, and acquired drug resistance---end-points with objective microbiological definitions that were consistent across trials. Therefore, we used a per-protocol analysis, excluding patients who did not complete therapy because they developed serious adverse reactions, died, defaulted, dropped out, or were otherwise not accounted for.

We restricted our first analysis to those trials within which regimens differed by the duration of rifampin, or dosing schedule (intermittency), but were otherwise comparable. To increase the number of trials with head-to-head comparisons analyzed, regimens were considered comparable even if they differed by ethambutol or thiacetazone. For each trial with head-to-head comparisons, we calculated cumulative incidence of failure, relapse, and acquired drug resistance, and the Mantel-Haenszel pooled difference in cumulative incidence and 95% confidence interval (CI) for each comparison [@pmed.1000146-Bradburn1]. One advantage of this method is that 0-cell corrections are not necessary to calculate the MH pooled risk difference [@pmed.1000146-Bradburn1]. We assessed heterogeneity of risk differences for each comparison, by estimating the I^2^ statistic and associated 95% CIs [@pmed.1000146-Higgin1]. For this calculation, studies in which both arms had no events were corrected by 0.5.

Because few trials with head-to-head comparisons were identified, in our second analysis we pooled results across all trials, effectively treating each arm within each trial as an independent cohort. For the across-trial analysis, we used a random effects meta-analysis to estimate the overall pooled estimates of cumulative incidence and 95% CI of failure, relapse, and acquired drug resistance using Proc Nlmixed in SAS (SAS Institute, Carey, NC, USA) [@pmed.1000146-Hamza1]. We used the exact binomial likelihood approach [@pmed.1000146-Hamza1], which uses a binomial distribution to approximate the distribution of the outcome of interest. This approach accounts for study size and includes a random effect to account for between-study heterogeneity. When proportions are the outcome measure, this approach has been demonstrated to produce less-biased estimates of the pooled effect and the between-study variability [@pmed.1000146-Hamza1]. We assessed heterogeneity of proportions of participants with outcomes of interest, within subgroups defined by covariates of interest by estimating the I^2^ statistic and associated 95% CIs [@pmed.1000146-Higgin1]. To calculate I^2^, 0-cells were corrected by 0.5.

To minimize heterogeneity, we performed subgroup analyses stratified by predefined covariates of interest. These included duration and dosing schedule of rifampin, initial drug resistance, use of pyrazinamide or streptomycin, and number of drugs to which the organism was susceptible used in the initial or continuation phase (the initial intensive phase was defined as the initial period when more drugs were used---usually the first 1--2 mo---while the continuation phase was the remainder of therapy). We also examined the effect of supervision of therapy (i.e. directly observed therapy \[DOT\]), proportion that were smear positive, and default or other losses during treatment phase follow-up.

Finally, meta-regression was used to estimate the effect of the treatment factors of interest, after adjustment for other potentially confounding patient and treatment covariates. Because the outcomes we were pooling were proportions rather than odds ratios, and because these proportions were usually small, we performed meta-regression using the Poisson model [@pmed.1000146-Glasziou1] that allowed for overdispersion (i.e., negative binomial regression). In this meta-regression, each arm in each study was the unit of analysis, cumulative incidence of TB treatment outcomes was the dependent variable, and TB treatment characteristics were the independent variables. An offset was used to account for size of study. In this approach, residual heterogeneity between studies is accounted for in the dispersion parameter. As such we interpreted the dispersion parameter as indicating there was no remaining unexplained heterogeneity if the value was not significantly different from zero and as minimal heterogeneity if the value was less than 1.0 [@pmed.1000146-Thompson1]. Effect estimates of the meta-regression model were interpreted as adjusted incidence rate ratios (IRR) [@pmed.1000146-Glasziou1]. We tested the significance of each factor in the models using the likelihood ratio test. Two models were used. The first included rifampin duration, intermittent schedule, use of pyrazinamide and streptomycin, number of drugs in initial or continuation phases to which organisms were susceptible, length of follow-up after end of treatment (for relapse and acquired drug resistance), directly observed therapy (DOT), and non-completion of therapy because of protocol violations, patient refusal, default, moved, or lost. The second model included initial drug resistance with all the same factors, except the number of sensitive drugs in initial or continuation phases---which could not be included because of substantial co-linearity between these factors and drug resistance.

Results {#s3}
=======

Description of Included Trials {#s3a}
------------------------------

As seen in [Figure 1](#pmed-1000146-g001){ref-type="fig"}, 2,215 citations were identified from the search of the three electronic databases. Of these, 237 were retained for abstract review and 166 for full text review. An additional 135 full texts were identified from the search of the references of the original articles and other sources. After full text review, 75 papers describing 57 randomized trials were selected for this analysis. These trials, summarized in Appendix Table 1 in [Text S1](#pmed.1000146.s002){ref-type="supplementary-material"} [@pmed.1000146-Singapore1]--[@pmed.1000146-Mohanty1], included a total of 21,472 participants in 312 different treatment arms. Of these, 612 patients died and 2,775 dropped out, were lost, or were otherwise not accounted for. This left 18,701 analyzable participants in all trials. Failure was analyzed for 18,085 participants in 56 studies; relapse was reported for 15,558 participants in 53 trials, while acquired drug resistance was reported for 11,400 participants in 39 trials ([Table 1](#pmed-1000146-t001){ref-type="table"}). All trials involved adults, and in 42 all patients were smear positive, although cultures were used to define study end-points in all but three trials [@pmed.1000146-Jindani1],[@pmed.1000146-SharifiMood1],[@pmed.1000146-Mohanty1]. Only four trials included HIV-infected persons, with a total of 522 HIV-infected participants. Rifampin dose was not stated in two trials [@pmed.1000146-GonzalezMontaner1],[@pmed.1000146-Mohanty1], was 450 mg/d in three trials with a total of 618 patients [@pmed.1000146-Hong8],[@pmed.1000146-Engbaek1],[@pmed.1000146-Kohno2], and was 600 mg/d (or 10--12 mg/kg) in all the remaining studies. In 30 trials (52%) all treatment doses were supervised, and in 29 (51%) less than 10% refused, defaulted, or were lost during treatment. Randomization was described in 41 trials, and was adequate in 40, but not described in 16 trials. Median post-treatment follow-up was 24 mo (interquartile range: 18--30).

![Summary of literature search and study selection.](pmed.1000146.g001){#pmed-1000146-g001}

10.1371/journal.pmed.1000146.t001

###### Summary of studies reviewed (all randomized controlled trials with rifampin-containing regimens in new cases).
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  Characteristic                           By Study   By Arm        
  --------------------------------------- ---------- -------- ----- ----
  **Language of publication**                                       
  English                                     54        95     299   96
  French                                      3         5      14    4
  **Year when study began**                                         
  1969--1979                                  26        45     178   56
  1980--1989                                  16        28     104   33
  1990--1999                                  13        24     26    9
  2000--Present                               2         3       5    2
  **Sponsorship**                                                   
  Public                                      56        98     311   99
  Corporate                                   1         2       2    1
  **Measured failure**                                              
  Yes                                         56        98     311   99
  No                                          1         2       2    1
  **Measured relapse**                                              
  Yes                                         53        93     302   97
  No                                          4         7      11    3
  **Measured acquired drug resistance**                             
  Yes                                         39        69     264   84
  No                                          18        31     49    16
  **Quality in treatment**                                          
  High (≤10% dropout/lost)                    29        51     182   58
  Poor (\>10% dropout/lost)                   28        49     131   42
  **Quality in follow-up**                                          
  High (≤10% lost)                            40        67     217   72
  Poor (\>10% lost)                           17        33     85    28
  **Quality of randomization**                                      
  Adequate                                    39        70     181   58
  Not stated or inadequate                    18        30     132   42
  **Blinding**                                                      
  Single or double                            4         7      14    4
  None                                        53        93     299   96
  **Supervision of rifampin**                                       
  None/partial                                27        47     49    16
  All doses                                   30        53     264   84
  **Isoniazid**                                                     
  Not used                                    0         0       1    1
  Used                                        57       100     312   99
  **Pyrazinamide**                                                  
  Not used                                    11        19     61    19
  Used                                        46        81     252   81
  **Streptomycin**                                                  
  Not used                                    28        49     101   32
  Used                                        29        51     212   68
  **Use of second line drugs**                                      
  None                                        55        99     312   99
  Yes -- (1 drug)                             2         1       2    1

  Parameters Varied Within Studies -- Summary by Arm Only    *N*   \%
  --------------------------------------------------------- ----- ----
  **Number of drugs used to which strains sensitive**             
  *Initial intensive phase*                                       
   1                                                          2    1
   2                                                         68    23
   3                                                         153   52
   4 or more                                                 71    24
  *Continuation phase*                                            
   0 or 1                                                    70    24
   2                                                         144   50
   3 or more                                                 74    26
  **Drug sensitivity**                                            
  Unknown (Mix)                                              19    6
  Pan-sensitive                                              128   41
  INH resistance                                             68    22
  Streptomycin                                               54    17
  Poly-drug resistance                                       44    14
  **Rifampin use and duration**                                   
  1--2 mo                                                    72    23
  3--4 mo                                                    42    13
  5--7 mo                                                    178   57
  8+ mo                                                      21    7
  **Schedule of administration**                                  
  Daily throughout                                           161   51
  Daily then thrice weekly                                   35    11
  Daily then twice weekly                                    45    15
  Thrice weekly throughout                                   70    22
  Twice weekly throughout                                     2    1

Results of Head-to-Head Comparisons {#s3b}
-----------------------------------

As seen in [Table 2](#pmed-1000146-t002){ref-type="table"}, in the studies with head-to-head comparisons, rates of failure ([Table 2](#pmed-1000146-t002){ref-type="table"}) were significantly higher in patients who received only 1--2 mo of rifampin than in patients who received longer durations of rifampin. Rates of relapse ([Table 3](#pmed-1000146-t003){ref-type="table"}) were progressively lower with longer duration of rifampin up to 8 mo or more. In the only trial which compared four different durations of rifampin (6 versus 9, 12, and 18 mo), all outcomes were the same with the three longer regimens [@pmed.1000146-British2],[@pmed.1000146-British6]. Acquired drug resistance ([Table 4](#pmed-1000146-t004){ref-type="table"}) was not associated with shorter duration of rifampin, but this outcome was uncommon and reported in fewer trials---limiting power. All five of the studies with head-to-head comparisons of intermittent schedules compared different regimens and schedules, so results could not be pooled ([Table 5](#pmed-1000146-t005){ref-type="table"}).

10.1371/journal.pmed.1000146.t002

###### Pooled risk differences from direct head-to-head comparisons of rifampin duration or intermittent schedules in otherwise comparable regimens: Failure.
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  Ref                                                       Regimens[a](#nt102){ref-type="table-fn"}      Fail       Non   Fail   Non   Risk Difference
  -------------------------------------------------------- ------------------------------------------ ------------- ----- ------ ----- -----------------
  ***2 versus 3--4 mo***                                                    **2 mo**                   **3--4 mo**                     
  [@pmed.1000146-East8],[@pmed.1000146-Hong10]                             2SHRZ/2HZ                        1        123    1     248        0.4%
                                                                           2SHRZ/2HR                                                   
  [@pmed.1000146-Hong8],[@pmed.1000146-Hong9]                                2SHRZ                          0        84     0     81           0
                                                                             3SHRZ                                                     
  Pooled risk difference (95% CI)                                     0.3% (0.9% to 1.4%)                                              
  Overall I^2^ (95% CI)                                                    0 (− , −)                                                   
  ***2 versus 6 mo***                                                       **2 mo**                    **6 mo**                       
  [@pmed.1000146-East5],[@pmed.1000146-East9]                              2SHRZ/4HZ                        3        206    0     212        1.4%
                                                                            SHRZ/4HR                                                   
  [@pmed.1000146-Jindani1]                                                 2EHRZ/6HE                       41        771    12    371        1.8%
                                                                           2EHRZ/4HR                                                   
  [@pmed.1000146-Felten2]                                              2HRZE/4\[HRZ\]~2~                    3        41     3     51         1.3%
                                                                       2HRZE/4\[HZE\]~2~                                               
  Pooled risk difference (95% CI)                                      1.7% (0% to 3.4%)                                               
  Overall I^2^ (95% CI)                                                  0 (0 to 0.73)                                                 
  ***4 versus 6 mo***                                                       **4 mo**                    **6 mo**                       
  [@pmed.1000146-Singapore3]--[@pmed.1000146-Singapore5]                   2SHRZ/2HR                        0        91     1     89         −1.1%
                                                                           2SHRZ/4HR                                                   
  [@pmed.1000146-Singapore3]--[@pmed.1000146-Singapore5]                   2SHRZ/2HRZ                       0        91     0     89          0%
                                                                           2SHRZ/4HRZ                                                  
  [@pmed.1000146-Algerian2]                                               2SHRZ/2HR/4H                      4        564    1     518        0.5%
                                                                           2SHRZ/4HR                                                   
  [@pmed.1000146-Teo1]                                                      2HRZ/2HR                        0        59     1     53         −2.0%
                                                                        2HRZ/4\[HR\]~3~                                                
  [@pmed.1000146-SharifiMood1]                                             2HRZE/2HR                        0        33     3     64         −4.5%
                                                                           2HRZE/4HR                                                   
  [@pmed.1000146-A1]                                                       2SHRZ/2HR                        0        79     0     83          0%
                                                                           2SHRZ/4HR                                                   
  [@pmed.1000146-A1]                                                       2SHRZ/2HRZ                       0        83     0     87          0%
                                                                           2SHRZ/4HRZ                                                  
  Pooled risk difference (95% CI)                                    −0.1% (−0.7% to 0.4%)                                             
  Overall I^2^ (95% CI)                                                 0.10 (0 to 0.7)                                                
  ***6 versus 9+ mo***                                                      **6 mo**                    **9+ mo**                      
  [@pmed.1000146-Hong6]                                                   6\[SHRZ\]~3~                      1        67     4     50         −5.9%
                                                                          8\[SHRZ\]~3~                                                 
  [@pmed.1000146-Perriens1]                                             2HRZE/4\[HR\]~2~                    5        129    4     131        0.8%
                                                                       2HRZE/10\[HR\]~2~                                               
  [@pmed.1000146-ElSadr1]                                                  2HRZE/4HR                        1        41     0     37         2.4%
                                                                           2HRZE/7HR                                                   
  [@pmed.1000146-British2],[@pmed.1000146-British3]                         2EHR/4HR                        1        116    0     282        0.9%
                                                                         2EHR/7,10,16HR                                                
  [@pmed.1000146-British2],[@pmed.1000146-British3]                         2SHR/4HR                        0        74     0     213         0%
                                                                         2SHR/7,10,16HR                                                
  Pooled risk difference (95% CI)                                    −0.2% (−1.9% to 1.5%)                                             
  Overall I^2^ (95% CI)                                                  0 (0 to 0.75)                                                 

Seventeen head-to-head comparisons of rifampin duration. For one study [@pmed.1000146-British2],[@pmed.1000146-British3], results with 9-, 12-, and 18-mo regimens were the same so they were combined.

Regimen abbreviations: H, isoniazid; R, rifampin; Z, pyrazinamide; E, ethambutol; S, streptomycin.

Letters to left of "/" indicate regimen in initial intensive phase; letters to right of "/" indicate regimen in continuation phase. First number signifies the months of initial phase of treatment and the second number signifies the months of continuation phase treatment. \[ \] indicates intermittent therapy; subscript number after \[ \] indicates number of doses per week.

10.1371/journal.pmed.1000146.t003

###### Pooled risk differences from direct head-to-head comparisons of rifampin duration or intermittent schedules in otherwise comparable regimens: Relapse.
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  Ref                                                       Regimens[a](#nt105){ref-type="table-fn"}     Relapse     Non   Relapse   Non   Risk Difference
  -------------------------------------------------------- ------------------------------------------ ------------- ----- --------- ----- -----------------
  ***2 versus 3--4 mo***                                                    **2 mo**                   **3--4 mo**                        
  [@pmed.1000146-East8],[@pmed.1000146-Hong10]                             2SHRZ/2HZ                       38        78      30      200        19.7%
                                                                           2SHRZ/2HRZ                                                     
  [@pmed.1000146-Hong8]                                                      2SHRZ                         20        64       8      73         13.9%
                                                                             3SHRZ                                                        
  Pooled risk difference (95% CI)                                     17.7% (10.3% to 25%                                                 
  Overall I^2^ (95% CI)                                                    0 (− , −)                                                      
  ***2 versus 6 mo***                                                       **2 mo**                    **6 mo**                          
  [@pmed.1000146-East5],[@pmed.1000146-East10]                             2SHRZ/4HZ                       13        168      6      171        3.8%
                                                                           2SHRZ/4HR                                                      
  [@pmed.1000146-Jindani1]                                                 2EHRZ/6HE                       57        344      6      236        11.7%
                                                                           2EHRZ/4HR                                                      
  [@pmed.1000146-Felten2]                                              2HRZE/4\[HRZ\]~2~                   20        21       6      45          37%
                                                                       2HRZE/4\[HZE\]~2~                                                  
  Pooled risk difference (95% CI)                                    11.2% (8.1% to 14.3%)                                                
  Overall I^2^ (95% CI)                                               0.88 (0.66 to 0.96)                                                 
  ***4 versus 6 mo***                                                       **4 mo**                    **6 mo**                          
  [@pmed.1000146-Singapore3]--[@pmed.1000146-Singapore5]                   2SHRZ/2HR                        7        80       2      83         5.7%
                                                                           2SHRZ/4HR                                                      
  [@pmed.1000146-Singapore3]--[@pmed.1000146-Singapore5]                   2SHRZ/2HRZ                      10        79       0      82         11.2%
                                                                           2SHRZ/4HRZ                                                     
  [@pmed.1000146-Algerian2]                                               2SHRZ/2HR/4H                     38        526     23      495        2.3%
                                                                           2SHRZ/4HR                                                      
  [@pmed.1000146-Teo1]                                                      2HRZ/2HR                        0        57       0      52          0%
                                                                        2HRZ/4\[HR\]~3~                                                   
  [@pmed.1000146-SharifiMood1]                                             2HRZE/2HR                        3        30       6      58         −0.3%
                                                                           2HRZE/4HR                                                      
  [@pmed.1000146-A1]                                                       2SHRZ/2HR                        4        70       1      79         4.2%
                                                                           2SHRZ/4HR                                                      
  [@pmed.1000146-A1]                                                       2SHRZ/2HRZ                       8        72       0      84         10.0%
                                                                           2SHRZ/4HRZ                                                     
  Pooled risk difference (95% CI)                                     6.9% (3.7% to 10.0%)                                                
  Overall I^2^ (95% CI)                                               0.59 (0.05 to 0.82)                                                 
  ***6 vs. 9+ mo***                                                         **6 mo**                    **9+ mo**                         
  [@pmed.1000146-Hong6]                                                   6\[SHRZ\]~3~                     12        44       2      40          17%
                                                                          8\[SHRZ\]~3~                                                    
  [@pmed.1000146-Perriens1]                                             2HRZE/4\[HR\]~2~                    9        59       1      53         11.4%
                                                                       2HRZE/10\[HR\]~2~                                                  
  [@pmed.1000146-Combs1]                                                    2HRZ/4HR                       10        375      6      225         0%
                                                                            2HRZ/7HR                                                      
  [@pmed.1000146-ElSadr1]                                                  2HRZE/4HR                        1        16       1      14         −0.8%
                                                                           2HRZE/7HR                                                      
  [@pmed.1000146-British2],[@pmed.1000146-British3]                         2EHR/4HR                        6        96       0      213        5.9%
                                                                         2EHR/7,10,16HR                                                   
  [@pmed.1000146-British2],[@pmed.1000146-British3]                         2SHR/4HR                        2        52       2      160        2.5%
                                                                         2SHR/7,10,16HR                                                   
  Pooled risk difference (95% CI)                                     4.0% (1.8% to 6.2%)                                                 
  Overall I^2^ (95% CI)                                               0.65 (0.18 to 0.86)                                                 

Eighteen head-to-head comparisons of rifampin duration. For one study [@pmed.1000146-British2],[@pmed.1000146-British3], results with 9-, 12-, and 18-mo regimens were the same so they were combined.

Regimen abbreviations: H, isoniazid; R, rifampin; Z, pyrazinamide; E, ethambutol; S, streptomycin.

Letters to left of "/" indicate regimen in initial intensive phase; letters to right of "/" indicate regimen in continuation phase. First number signifies the months of initial phase of treatment and the second number signifies the months of continuation phase treatment. \[ \] indicates intermittent therapy; subscript number after \[ \] indicates number of doses per week.

10.1371/journal.pmed.1000146.t004

###### Pooled risk differences from direct head-to-head comparisons of rifampin duration or intermittent schedules in otherwise comparable regimens: Acquired drug resistance.
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  Ref                                                       Regimens[a](#nt108){ref-type="table-fn"}     ADR      Non   ADR   Non   Risk Difference
  -------------------------------------------------------- ------------------------------------------ ---------- ----- ----- ----- -----------------
  ***2 versus 4 mo***                                                       **2 mo**                   **4 mo**                    
  [@pmed.1000146-Hong8]                                                      2SHRZ                        0       84     0    81           0
                                                                             3SHRZ                                                 
  Pooled risk difference (95% CI)                                              0%                                                  
  Overall I^2^ (95% CI)                                                   0 (-- , --)                                              
  ***2 versus 6 mo***                                                       **2 mo**                   **6 mo**                    
  [@pmed.1000146-East5],[@pmed.1000146-East11]                             2SHRZ/4HZ                      3       206    2    210        0.5%
                                                                           2SHRZ/4HR                                               
  Pooled risk difference (95% CI)                                     0.5% (−1.5% to 2.5%)                                         
  Overall I^2^ (95% CI)                                                   0 (-- , --)                                              
  ***4 versus 6 mo***                                                       **4 mo**                   **6 mo**                    
  [@pmed.1000146-Singapore3]--[@pmed.1000146-Singapore5]                   2SHRZ/2HR                      1       90     1    89          0%
                                                                           2SHRZ/4HR                                               
  [@pmed.1000146-Singapore3]--[@pmed.1000146-Singapore5]                   2SHRZ/2HRZ                     0       91     0    89          0%
                                                                           2SHRZ/4HRZ                                              
  [@pmed.1000146-Algerian2]                                              2SHRZ/2HR/4HR                    5       563    1    518        0.7%
                                                                           2SHRZ/4HR                                               
  [@pmed.1000146-A1]                                                       2SHRZ/2HR                      0       79     0    83          0%
                                                                           2SHRZ/4HR                                               
  [@pmed.1000146-A1]                                                       2SHRZ/2HRZ                     0       83     0    87          0%
                                                                           2SHRZ/4HRZ                                              
  Pooled risk difference (95% CI)                                     0.4% (−0.2% to 1.0%)                                         
  Overall I^2^ (95% CI)                                                  0 (0 to 0.74)                                             
  ***6 versus 9 mo***                                                       **6 mo**                   **9 mo**                    
  [@pmed.1000146-Hong6]                                                   6\[SHRZ\]~3~                    2       66     4    50         −4.5%
                                                                          8\[SHRZ\]~3~                                             
  [@pmed.1000146-ElSadr1]                                                  2HRZE/4HR                      2       40     2    35         −0.6%
                                                                           2HRZE/7HR                                               
  [@pmed.1000146-British2],[@pmed.1000146-British3]                         2EHR/4HR                      0       117    0    282         0%
                                                                         2EHR/7,10,16HR                                            
  [@pmed.1000146-British2],[@pmed.1000146-British3]                         2SHR/4HR                      0       74     0    213         0%
                                                                         2SHR/7,10,16HR                                            
  Pooled risk difference (95% CI)                                    −0.8% (−2.4% to 0.9%)                                         
  Overall I^2^ (95% CI)                                                  0 (0 to 0.77)                                             

Eleven head-to-head comparisons of rifampin duration. For one study [@pmed.1000146-British2],[@pmed.1000146-British3]---results with 9-, 12-, and 18-mo regimens were the same---so they were combined.

Regimen abbreviations: H, isoniazid; R, rifampin; Z, pyrazinamide; E, ethambutol; S, streptomycin.

Letters to left of "/" indicate regimen in initial intensive phase; letters to right of "/" indicate regimen in continuation phase. First number signifies the months of initial phase of treatment and the second number signifies the months of continuation phase treatment. \[ \] indicates intermittent therapy; subscript number after \[ \] indicates number of doses per week.

10.1371/journal.pmed.1000146.t005

###### Pooled risk differences from direct head-to-head comparisons of rifampin duration or intermittent schedules otherwise comparable regimens.

![](pmed.1000146.t005){#pmed-1000146-t005-5}

  Reference                                                                          Drug Resistance Patterns                  Treatment Regimens[](#nt111){ref-type="table-fn"} [a](#nt113){ref-type="table-fn"}   Treated (*N*)   Failed (*N*)   Relapsed (*N*)^b^   ADR (*N*)^b^
  ------------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------------------------------------ --------------- -------------- ------------------- --------------
  [@pmed.1000146-Zierski2],[@pmed.1000146-Zierski3]                                        Pan-sensitive                                                        2HRE/4\[HR\]~2~                                          93              0                16                0
                                                                                                                                                                2HRE/4\[HRE\]~2~                                         96              0                 6                0
                                                                                                                                                                      6HRE                                               98              0                12                0
  [@pmed.1000146-Hong1],[@pmed.1000146-Hong4],[@pmed.1000146-Hong5]               Pan-sensitive, STREP, INH, PDR                                                     6HRZE                                               199             0                 6                0
                                                                                                                                                                  6\[HRZE\]~3~                                           199             1                 8                0
  [@pmed.1000146-Jindani1]                                             Pan-sensitive plus all forms of resistance except MDR                                       2EHRZ/6HE                                             402             18                1               n/a
                                                                                                                                                                2\[EHRZ\]~3~/6HE                                         410             22                1               n/a
  [@pmed.1000146-Teo1]                                                                     Pan-sensitive                                                            2HRZ/2HR                                             158             0                 0               n/a
                                                                                                                                                                2HRZ/2\[HR\]~3~                                          102             0                 1               n/a
  [@pmed.1000146-Macnab2]                                              Pan-sensitive plus all forms of resistance except MDR                               3\[HRZE\]~5~/3.5\[HR\]~5~                                     39              0                n/a              n/a
                                                                                                                                                               6.5HRZ (with FDC)                                         67              0                n/a              n/a

Treatment outcomes are from five studies with direct head-to head-comparisons of intermittency schedules (and otherwise comparable regimens). Meta-analysis not done, as no schedules were the same.

Regimen abbreviations: H, isoniazid; R, rifampin; Z, pyrazinamide; E, ethambutol; S, streptomycin.

Letters to left of "/" indicate regimen in initial intensive phase; letters to right of "/" indicate regimen in continuation phase. First number signifies the months of initial phase of treatment and the second number signifies the months of continuation phase treatment. \[ \] indicate intermittent therapy; subscript number after \[ \] indicates number of doses per week.

n/a, not available, meaning relapse and/or acquired drug resistance (ADR) not measured.

INH, isoniazid resistant; STREP, streptomycin resistant; PDR, poly-drug resistant (streptomycin+isoniazid resistant); FDC, fixed drug combinations.

Pooled Results across Trials {#s3c}
----------------------------

When results were pooled across all 57 trials, rifampin was given for 1 mo in 12 arms, 2 mo in 60, 5 mo in 6, 6 mo in 170, and 7 mo in 2. Regimens with 1--2 mo of rifampin had higher failure ([Table 6](#pmed-1000146-t006){ref-type="table"}) and relapse ([Table 7](#pmed-1000146-t007){ref-type="table"}) rates than regimens with longer duration rifampin. Relapse rates were progressively lower with longer rifampin duration, up to 8 mo or more of rifampin (see [Figure S1](#pmed.1000146.s001){ref-type="supplementary-material"}).

10.1371/journal.pmed.1000146.t006

###### Stratified estimates of treatment failures in RCT in new cases.
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  Factor                                                                               Studies (*N*)   Events/Participants (*N*)   Pooled Event Rate (Across All Trials)       95% CI           I^2^ (95% CI)
  ----------------------------------------------------------------------------------- --------------- --------------------------- --------------------------------------- ----------------- ---------------------
  **Duration of rifampin**                                                                                                                                                                  
   Rifampin 1--2 mo                                                                         72                 94/4,133                             1.8                      0.2 to 3.3      0.36 (0.15 to 0.52)
   Rifampin 3--5 mo                                                                         42                 16/2,508                             0.3                       0 to 0.6          0 (0 to 0.35)
   Rifampin 6--7 mo                                                                         178               150/10,060                            0.4                      0.1 to 0.7         0 (0 to 0.19)
   Rifampin 8+ mo                                                                           18                 10/1,384                             0.2                       0 to 0.6          0 (0 to 0.49)
  **Use of intermittent therapy**                                                                                                                                                           
   Daily throughout                                                                         159               179/11,510                            0.4                      0.2 to 0.7       0.07 (0 to 0.24)
   Daily then thrice weekly                                                                 35                   4/961                              0.3                       0 to 1.0          0 (0 to 0.38)
   Daily then twice weekly                                                                  46                 49/2,749                             1.2                      0.1 to 2.4       0.21 (0 to 0.45)
   Thrice weekly throughout[a](#nt116){ref-type="table-fn"}                                 70                 38/2,865                             0.5                       0 to 1.0          0 (0 to 0.28)
  **Initial drug resistance**                                                                                                                                                               
   DST not done/reported                                                                    19                 78/2,105                             2.2                       0 to 4.4          0 (0 to 0.48)
   Sensitive to all TB drugs                                                                126               120/14,900                            0.3                      0.1 to 0.4         0 (0 to 0.21)
   Isoniazid resistance                                                                     67                  25/477                            **2.8**                  **0.7 to 5.0**       0 (0 to 0.29)
   Streptomycin resistance                                                                  54                   6/316                              1.3                       0 to 2.7          0 (0 to 0.31)
   INH+streptomycin resistant (PDR)                                                         44                  41/287                            **8.3**                  **1.9 to 14.7**      0 (0 to 0.34)
  **Duration of pyrazinamide**                                                                                                                                                              
   No pyrazinamide                                                                          59                 97/4,831                             0.3                       0 to 0.6       0.30 (0.03 to 0.49)
   1--3 mo                                                                                  139                124/8,287                            0.6                      0.2 to 1.0         0 (0 to 0.21)
   4+ mo                                                                                    112                49/4,967                             0.5                      0.1 to 0.8         0 (0 to 0.23)
  **Duration of streptomycin**                                                                                                                                                              
   No streptomycin                                                                          100                188/7,907                            0.6                      0.2 to 0.9       0.18 (0 to 0.36)
   1--3 mo                                                                                  117                44/6,328                             0.4                      0.1 to 0.6         0 (0 to 0.23)
   4+ mo                                                                                    93                 38/3,850                             0.5                       0 to 0.9          0 (0 to 0.25)
  **Number of drugs to which strains susceptible** [b](#nt117){ref-type="table-fn"}                                                                                                         
  *Initial phase*                                                                                                                                                                           
   0--1 drugs                                                                                2                   10/29                             33.2                      0 to 103.5          0 (--, --)
   2 drugs                                                                                  66                 114/1,782                            2.8                      0.2 to 5.2      0.52 (0.36 to 0.63)
   3 drugs                                                                                  151                43/5,664                             0.3                       0 to 0.5          0 (0 to 0.20)
   4 drugs                                                                                  72                 25/8,505                             0.1                       0 to 0.1          0 (0 to 0.28)
  *Continuation phase*                                                                                                                                                                      
   0--1 drugs                                                                               69                  54/588                            **2.6**                   **0 to 6.1**        0 (0 to 0.28)
   2 drugs                                                                                  142                113/9,838                            0.2                      0.1 to 0.4         0 (0 to 0.20)
   3 or more drugs                                                                          74                 25/5,528                             0.1                       0 to 0.2          0 (0 to 0.27)
  **Supervision of therapy**                                                                                                                                                                
   All doses fully supervised                                                               232               145/10,446                            0.4                      0.1 to 0.7         0 (0 to 0.16)
   None or partial DOT                                                                      78                 125/7,639                            0.4                      0.1 to 0.7       0.19 (0 to 0.39)
  **Completion of therapy**                                                                                                                                                                 
   Good (≤10% dropouts)                                                                     181               102/11,837                            0.3                      0.1 to 0.5         0 (0 to 0.19)
   Poor (\>10% dropouts)                                                                    129                168/6,248                            0.9                      0.3 to 1.5      0.25 (0.07 to 0.40)

Event rate and 95% CI are in bold if confidence intervals for two or more strata do not overlap.

In all but one trial, if therapy was intermittent initially, the same schedule was continued throughout therapy.

In a few trials, the number of drugs was the same throughout---these were classified according to the starting regimen.

10.1371/journal.pmed.1000146.t007

###### Stratified estimates of relapse in RCT in new cases.
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  Factor                                                                               Studies (*N*)   Events/Participants (*N*)   Pooled Event Rate (Across All Trials)        95% CI           I^2^ (95% CI)
  ----------------------------------------------------------------------------------- --------------- --------------------------- --------------------------------------- ------------------ ---------------------
  **Overall**                                                                                                                                                                                
  *Duration of rifampin*                                                                                                                                                                     
   Rifampin 1--2 mo                                                                         70                 367/3,349                         **16.0**                  **11.1 to 20.9**   0.67 (0.58 to 0.74)
   Rifampin 3--5 mo                                                                         42                 185/2,389                          **7.1**                   **4.5 to 9.7**    0.65 (0.52 to 0.75)
   Rifampin 6--7 mo                                                                         171                364/8,639                          **3.8**                   **2.9 to 4.7**       0 (0 to 0.19)
   Rifampin 8+ mo                                                                           18                 14/1,181                             1.0                       0.2 to 1.7         0 (0 to 0.46)
  *Use of intermittent therapy*                                                                                                                                                              
   Daily throughout                                                                         153                566/9,829                            4.8                       3.6 to 6.0      0.56 (0.49 to 0.64)
   Daily then thrice weekly                                                                 34                  33/907                              2.9                       0.7 to 5.2         0 (0 to 0.38)
   Daily then twice weekly                                                                  44                 181/2,367                            7.3                      4.0 to 10.7      0.6 (0.45 to 0.71)
   Thrice weekly throughout[a](#nt119){ref-type="table-fn"}                                 70                 150/2,455                            5.7                       3.1 to 8.3       0.23 (0 to 0.43)
  **Initial drug resistance**                                                                                                                                                                
   DST not done/reported                                                                    17                 124/1,337                            7.8                      3.0 to 12.5      0.82 (0.73 to 0.88)
   Sensitive to all TB drugs                                                                123               684/13,302                            3.7                       2.8 to 4.7      0.66 (0.59 to 0.72)
   Isoniazid resistance                                                                     65                  60/403                           **11.4**                  **6.5 to 16.2**     0 (0 to 0.28**)**
   Streptomycin resistance                                                                  54                  36/299                              9.7                      4.6 to 14.9         0 (0 to 0.32)
   INH+streptomycin resistant (PDR)                                                         42                  26/217                             10.1                      4.2 to 15.9       0 to (0 to 0.34)
  **Duration of pyrazinamide**                                                                                                                                                               
   No pyrazinamide                                                                          56                 197/3,532                            5.1                       2.8 to 7.4      0.67 (0.58 to 0.75)
   1--3 mo                                                                                  136                445/7,539                            4.9                       3.5 to 6.4      0.46 (0.34 to 0.56)
   4+ mo                                                                                    109                288/4,487                            6.1                       3.9 to 8.2      0.38 (0.22 to 0.51)
  **Duration of streptomycin**                                                                                                                                                               
   No streptomycin                                                                          95                 286/6,277                            2.7                       1.8 to 3.6      0.44 (0.29 to 0.56)
   1--3 mo                                                                                  115                441/5,680                            7.5                       5.5 to 9.6      0.65 (0.61 to 0.73)
   4+ mo                                                                                    91                 203/3,601                            5.6                       3.4 to 7.7      0.27 (0.06 to 0.44)
  **Number of drugs to which strains susceptible** [b](#nt120){ref-type="table-fn"}                                                                                                          
  *Initial phase*                                                                                                                                                                            
   0--1 drugs                                                                                2                   2/17                               9.3                      0.0 to 30.2          0 (--, --)
   2 drugs                                                                                  63                 72/1,210                             6.6                      2.7 to 10.4       0.06 (0 to 0.31)
   3 drugs                                                                                  148                284/5,191                            4.1                       2.6 to 5.6      0.36 (0.22 to 0.47)
   4 drugs                                                                                  71                 448/7,803                            4.1                       2.4 to 5.8      0.66 (0.57 to 0.74)
  *Continuation phase*                                                                                                                                                                       
   0--1 drugs                                                                               66                  56/487                              7.6                      3.3 to 11.9         0 (0 to 0.28)
   2 drugs                                                                                  140                438/8,884                            3.8                       2.5 to 5.1      0.54 (0.45 to 0.62)
   3 or more drugs                                                                          72                 307/4,824                            4.5                       2.4 to 6.5      0.54 (0.40 to 0.65)
  **Supervision of therapy**                                                                                                                                                                 
   All doses fully supervised                                                               225                693/9,323                            7.3                       5.8 to 8.8      0.48 (0.39 to 0.55)
   None or partial DOT                                                                      76                 237/6,235                            2.4                       1.6 to 3.2      0.43 (0.26 to 0.56)
  **Completion of therapy**                                                                                                                                                                  
   Good (≤10% dropouts)                                                                     175               640/10,340                            5.5                       4.1 to 6.8      0.56 (0.48 to 0.63)
   Poor (\>10% dropouts)                                                                    126                290/5,218                            4.6                       3.2 to 6.1      0.42 (0.29 to 0.53)

Event rate and 95% CI are in bold if confidence intervals for two or more strata do not overlap.

In all but one trial, if therapy was intermittent initially, the same schedule was continued throughout therapy.

In a few trials the number of drugs was the same throughout---these were classified according to the starting regimen.

With regard to the different intermittent schedules compared, evidence regarding therapy given twice weekly throughout was limited to a single study of 223 patients who received 12 mo of isoniazid and rifampin---daily or twice weekly [@pmed.1000146-Singapore1],[@pmed.1000146-Singapore2]. Rates of failure, relapse, and acquired drug resistance were less than 1%. Because this was a single study, these results could not be pooled and are not considered further in stratified or multivariate analyses. The other schedules, of daily, daily then thrice weekly, daily then twice weekly, and thrice weekly throughout, were evaluated in numerous studies. As seen in [Tables 6](#pmed-1000146-t006){ref-type="table"}--[](#pmed-1000146-t007){ref-type="table"} [8](#pmed-1000146-t008){ref-type="table"}, there were no significant differences in outcomes between these four different treatment schedules.

10.1371/journal.pmed.1000146.t008

###### Stratified estimates of acquired drug resistance in RCT in new cases.

![](pmed.1000146.t008){#pmed-1000146-t008-8}

  Factor                                                                               Arms (*N*)   Events/Participants (*N*)   Pooled Event Rate (Across All Trials)       95% CI        I^2^ (95% CI)
  ----------------------------------------------------------------------------------- ------------ --------------------------- --------------------------------------- ----------------- ---------------
  **Overall**                                                                                                                                                                            
  *Rifampin use* [a](#nt122){ref-type="table-fn"}                                                                                                                                        
   Rifampin 1--2 mo                                                                        61               41/2,847                             0.8                       0 to 1.6       0 (0 to 0.28)
   Rifampin 3--5 mo                                                                        33               10/1,932                             0.3                       0 to 0.6       0 (0 to 0.35)
   Rifampin 6--7 mo                                                                       146               60/7,180                             0.4                      0.1 to 0.7      0 (0 to 0.19)
   Rifampin 8+ mo                                                                          17                6/1,249                             0.2                       0 to 0.5       0 (0 to 0.46)
  *Use of intermittent therapy* [a](#nt122){ref-type="table-fn"}                                                                                                                         
   Daily throughout                                                                       125               67/8,541                             0.3                      0.1 to 0.6      0 (0 to 0.20)
   Daily then thrice weekly                                                                28                 3/636                              0.6                       0 to 1.8       0 (0 to 0.38)
   Daily then twice weekly                                                                 36               12/1,748                             0.4                       0 to 1.0       0 (0 to 0.34)
   Thrice weekly throughout                                                                68               35/2,283                             0.9                       0 to 2.0       0 (0 to 0.28)
  **Initial drug resistance**                                                                                                                                                            
   Sensitive to all TB drugs                                                              106               70/12,256                            0.3                      0.1 to 0.4      0 (0 to 0.22)
   Isoniazid resistance                                                                    58                13/380                            **2.4**                  **0.5 to 4.4**    0 (0 to 0.29)
   Streptomycin resistance                                                                 52                12/313                              2.6                      0.3 to 5.0      0 (0 to 0.32)
   INH+streptomycin resistant (PDR)                                                        41                22/259                            **5.7**                  **1.3 to 10.1**   0 (0 to 0.34)
  **Duration of pyrazinamide**                                                                                                                                                           
   No pyrazinamide                                                                         48               26/3,662                             0.2                       0 to 0.3       0 (0 to 0.30)
   1--3 mo                                                                                113               46/5,536                             0.5                      0.1 to 0.9      0 (0 to 0.20)
   4+ mo                                                                                   96               45/4,010                             0.5                      0.1 to 1.0      0 (0 to 0.23)
  **Duration of streptomycin**                                                                                                                                                           
   No streptomycin                                                                         68               31/4,314                             0.3                       0 to 0.5       0 (0 to 0.24)
   1--3 mo                                                                                101               51/5,585                             0.4                      0.1 to 0.7      0 (0 to 0.23)
   4+ mo                                                                                   88               35/3,309                             0.8                      0.1 to 1.6      0 (0 to 0.25)
  **Number of drugs to which strains susceptible** [b](#nt123){ref-type="table-fn"}                                                                                                      
  *Initial phase*                                                                                                                                                                        
   0--1 drugs                                                                              1                  6/17                              34.5                      0 to 107.7       0 (--, --)
   2 drugs                                                                                 57                26/919                            **2.8**                  **0.6 to 5.0**    0 (0 to 0.29)
   3 drugs                                                                                136               47/4,899                             0.5                      0.2 to 0.8      0 (0 to 0.20)
   4 drugs                                                                                 63               38/7,373                             0.2                       0 to 0.3       0 (0 to 0.28)
  *Continuation phase*                                                                                                                                                                   
   0--1 drugs                                                                              62                26/511                            **2.8**                  **0.4 to 5.3**    0 (0 to 028)
   2 drugs                                                                                126               65/8,037                             0.4                      0.1 to 0.6      0 (0 to 0.20)
   3 or more drugs                                                                         63               26/4,634                             0.2                       0 to 0.4       0 (0 to 0.27)
  **Supervision of therapy**                                                                                                                                                             
   All doses fully supervised                                                             200               101/8,364                            0.7                      0.3 to 1.2      0 (0 to 0.17)
   None or partial DOT                                                                     57               16/4,844                             0.1                       0 to 0.3       0 (0 to 0.27)
  **Completion of therapy**                                                                                                                                                              
   Good (≤10% dropouts)                                                                   148               71/9,483                             0.3                      0.1 to 0.5      0 (0 to 0.19)
   Poor (\>10% dropouts)                                                                  109               46/3,725                             1.1                      0.3 to 1.8      0 (0 to 0.22)

Event rate and 95% CI are in bold if confidence intervals for two or more strata do not overlap.

In all but one trial, if therapy was intermittent initially, the same schedule was continued throughout therapy.

In a few trials the number of drugs was the same throughout---these were classified according to the starting regimen.

Of the other factors considered, initial drug resistance was associated with increased risk of failure, relapse, and acquired drug resistance. In the presence of initial isoniazid or isoniazid and streptomycin resistance (poly-drug resistance ), regimens using 1--2 mo of rifampin had failure rates of 6.5% (95% CI: 0.7%--12.3%) or 29% (10%--53%), respectively, in comparison with 0.2% (0%--0.5%) in pan-sensitive TB, and relapse rates of 38% (29%--46%) or 27% (10%--44%), respectively, compared to 8.2% (4.5%--11.9%) in pan-sensitive TB. Acquired drug resistance was also increased if there was initial drug resistance, but this effect appeared similar with all durations of rifampin. Interestingly, failure and acquired drug resistance were progressively lower with use of more drugs to which the organisms were sensitive in the initial phase (up to four drugs), and also associated (but less strongly) with the number of drugs to which the organisms were sensitive in the continuation phase.

Meta-Regression {#s3d}
---------------

When adjusted for potentially confounding treatment factors in multivariate regression, regimens with 1--2 mo of rifampin were associated with significantly higher failure, relapse, and acquired drug resistance rates than the reference group of 6 mo of rifampin ([Table 9](#pmed-1000146-t009){ref-type="table"}). Interestingly, adjusted relapse rates were lower with regimens using rifampin for at least 8 mo than with the 6-mo rifampin reference group. None of the intermittent schedules was significantly associated with failure or relapse, although acquired drug resistance was increased with two of the three intermittent regimens. Streptomycin use was protective against failure, relapse, and acquired drug resistance, while pyrazinamide use was protective only for relapse.

10.1371/journal.pmed.1000146.t009

###### Adjusted incidence rate ratios of failure, relapse, and acquired drug resistance (from negative binomial regression).
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  Factor                                                                  Failure IRR (95% CI)    Relapse IRR (95% CI)    Acquired Drug Resistance[a](#nt124){ref-type="table-fn"} IRR (95% CI)
  ---------------------------------------------------------------------- ----------------------- ----------------------- -----------------------------------------------------------------------
  **Duration of rifampin** [b](#nt125){ref-type="table-fn"}                                                              
   1--2 mo                                                                **5.8 (2.9 to 11.0)**   **3.6 (2.5 to 5.3)**                            **4.6 (2.0 to 0.4)**
   3--4 mo                                                                  1.3 (0.6 to 3.0)      **2.6 (1.6 to 4.0)**                              1.2 (0.4 to 3.1)
   5--7 mo                                                                   1.0 (reference)         1.0 (reference)                                 1.0 (reference)
   8+ mo                                                                    2.0 (0.8 to 4.9)      **0.4 (0.2 to 0.7)**                              2.1 (0.8 to 5.3)
  Overall significance (*p* value)[c](#nt126){ref-type="table-fn"}             (\<0.0001)              (\<0.0001)                                       (\<0.002)
  **Schedule of drug administration** [b](#nt125){ref-type="table-fn"}                                                   
   Daily throughout                                                          1.0 (reference)         1.0 (reference)                                 1.0 (reference)
   Daily then thrice weekly                                                 0.7 (0.2 to 2.1)        1.0 (0.6 to 1.5)                                0.7 (0.2 to 2.6)
   Daily then twice weekly                                                  0.9 (0.5 to 1.6)        0.8 (0.5 to 1.2)                                0.5 (0.3 to 1.2)
   Thrice weekly throughout                                                 0.7 (0.3 to 1.4)        1.2 (0.8 to 1.6)                              **2.4 (1.05 to 5.5)**
  Overall significance (*p* value)[c](#nt126){ref-type="table-fn"}               (0.66)                  (0.38)                                          (0.02)
  **Other Factors**                                                                                                      
  *Initial drug resistance* [d](#nt127){ref-type="table-fn"}                                                             
   DST not done/reported                                                  **3.3 (1.5 to 7.2)**    **3.0 (1.6 to 4.9)**                                     N/A
   Pan-sensitive strain                                                      1.0 (reference)         1.0 (reference)                                 1.0 (reference)
   Isoniazid resistant                                                    **10.9 (5.9 to 20)**    **1.8 (1.2 to 2.6)**                            **5.1 (2.3 to 11.0)**
   Streptomycin resistant                                                 **3.9 (1.4 to 11.0)**     1.4 (0.9 to 2.2)                              **4.1 (1.6 to 10.0)**
   Poly-drug resistant (PDR)                                                **33 (16 to 62)**     **1.8 (1.1 to 2.9)**                           **10.0 (4.5 to 22.1)**
  Overall significance (*p* value)[c](#nt126){ref-type="table-fn"}             (\<0.0001)              (\<0.0001)                                      (\<0.0001)
  **Use of pyrazinamide** [b](#nt125){ref-type="table-fn"}                                                               
   Pyrazinamide not used                                                     1.0 (reference)         1.0 (reference)                                 1.0 (reference)
   Pyrazinamide used                                                      **4.7 (2.4 to 9.0)**    **0.7 (0.4 to 0.95)**                           **2.4 (1.1 to 4.9)**
  Overall significance (*p* value)[c](#nt126){ref-type="table-fn"}             (\<0.0001)                (0.04)                                          (0.02)
  **Use of streptomycin** [b](#nt125){ref-type="table-fn"}                                                               
   Streptomycin not used                                                     1.0 (reference)         1.0 (reference)                                 1.0 (reference)
   Streptomycin used                                                      **0.3 (0.2 to 0.6)**      0.9 (0.6 to 1.3)                                0.7 (0.4 to 1.3)
  Overall significance (*p* value)[c](#nt126){ref-type="table-fn"}              (0.0003)                 (0.67)                                           (0.3)
  **Number of drugs to which strains susceptible\***                                                                     
  *Initial phase*                                                                                                        
   0--1 drugs                                                               **99 (33 to 99)**       1.6 (0.2 to 11.0)                              **74 (8.1 to 99)**
   2 drugs                                                                 **20 (8.2 to 49)**       1.1 (0.6 to 1.8)                               **6.7 (2.8 to 16)**
   3 drugs                                                                **2.6 (1.3 to 5.0)**      1.1 (0.8 to 1.5)                              **2.9 (1.5 to 5.5)**
   4 or more drugs                                                           1.0 (reference)         1.0 (reference)                                 1.0 (reference)
  Overall significance (*p* value)[c](#nt126){ref-type="table-fn"}             (\<0.0001)                 (0.9)                                         (0.0004)
  *Continuation phase*                                                                                                   
   0--1 drugs                                                               1.1 (0.4 to 2.6)        1.2 (0.7 to 2.0)                              **2.9 (1.1 to 7.3)**
   2 drugs                                                                **0.5 (0.2 to 0.9)**      0.8 (0.5 to 1.05)                               1.7 (0.9 to 3.2)
   3 or more drugs                                                           1.0 (reference)         1.0 (reference)                                 1.0 (reference)
  Overall significance (*p* value)[c](#nt126){ref-type="table-fn"}               (0.01)                  (0.08)                                          (0.08)

Acquired drug resistance in both failure and relapse cases combined.

Adjusted estimates of Incidence Rate Ratios (IRR) from multivariate negative binomial regression with model that included all variables indicated, plus length of follow-up after end of treatment (for relapse and acquired drug resistance), supervision of therapy (DOT), and non-completion of therapy because of protocol violations, patient refusal, default, moved, or lost. Estimates that are statistically significant are in bold.

Overall significance of each factor in multi-variate models, from log likelihood ratio test.

Adjusted estimates of IRR from second model that included initial drug resistance, and all the same factors, but not the number of sensitive drugs in initial or continuation phases. These could not be included because of substantial co-linearity with drug resistance.

The proportion smear positive, proportion HIV infected, and duration of post-treatment follow-up were not associated with treatment outcomes and were not included in final regression models. Poor completion of treatment was associated with failure or relapse, whereas supervision of therapy was not; both factors were included in final multivariate models, although estimates are not shown. Dispersion estimates for all three final models were less than 1, suggesting that the treatment factors included in these models accounted for the majority of the heterogeneity in outcomes seen.

Discussion {#s4}
==========

In this review of 57 trials with rifampin-containing regimens, use of rifampin only initially rather than throughout treatment was associated with worse treatment outcomes (higher rates of failure, relapse, and acquired drug resistance). Thrice-weekly intermittent dosing schedules during the initial treatment phase were associated with increased adjusted risk of acquired drug resistance, but not relapse or failure. Initial drug resistance was strongly associated with increased risk of poor treatment outcomes, particularly if rifampin was used only in the initial intensive phase. These findings have important implications for TB treatment.

The most important finding of this review is that all three treatment outcomes were significantly worse with regimens that used rifampin for the first 1--2 mo rather than throughout therapy. This finding adds considerable weight to similar findings by Jindani and colleagues, who compared regimens containing 2 mo versus 6 mo of rifampin [@pmed.1000146-Jindani1]. This review includes many more studies with a variety of regimens, making these results more robust and generalizable. In this review, the failure and relapse rates progressively declined with long duration of rifampin; such a dose--response relationship strengthens the conclusions that a longer duration of rifampin treatment is responsible for better outcomes. Finally, this review included studies where drug sensitivity testing was performed, which permitted us to detect an increased risk of acquired drug resistance with shorter rifampin duration and also permitted stratified analysis by underlying drug resistance, which proved to be a very important determinant of treatment outcomes. According to the most recent information from WHO [@pmed.1000146-Mak1], the 8-mo regimen was the recommended initial therapy in 24 high-incidence countries. Based on the pooled risk differences from within trial analyses, we estimate that treatment of 100 patients with the regimen of 2HRZE/6HE (the "8-mo" regimen) would result in 13 more failures and relapses than if they received 2HRZE/4HR (the "6-mo" regimen). As a result, forthcoming recommendations by WHO will recommend only the 6-mo (rifampin throughout) regimen, and the 8-mo regimen will no longer be recommended [@pmed.1000146-World4]. Results of this review suggest that the public health benefits of switching from the 8-mo to the 6-mo regimen should be very considerable.

The lower risk of relapse with regimens using rifampin for at least 8 mo is consistent with subgroup analyses of other trials [@pmed.1000146-Benator1] and a recent cohort report from Hong Kong [@pmed.1000146-Chang1]. These have shown that patients with extensive cavitary pulmonary disease have increased risk of relapse with 6-mo regimens. Taken together these findings support recommendations to extend therapy for patients at high risk of relapse [@pmed.1000146-American1]. However, accurate identification of high-risk patients is imprecise, and provision of extended therapy may be challenging in high-burden settings.

The lack of effect of intermittency is interesting but has several caveats. The timing of intermittent dosing may be quite important, as suggested by the finding of increased risk of acquired resistance associated with thrice-weekly therapy throughout. A cohort study from New York City reported that patients with HIV--TB coinfection had an increased risk of acquired rifamycin resistance if they were treated with twice-weekly therapy during the initial intensive phase but not if they were treated with intermittent dosing only during the continuation phase [@pmed.1000146-Li1].

Te other important finding is the previously underestimated impact of primary isoniazid resistance on failure, relapse, and acquired resistance. This important effect is a powerful argument for widespread availability of rapid, inexpensive testing for resistance to isoniazid (as well as for rifampin), or for regimens that do not require optimal activity from isoniazid. The influence of primary streptomycin resistance is likely to be less important, since streptomycin has been replaced by ethambutol in most settings.

The primary objective of this review was to compare the efficacy of different durations and dosing schedule of rifampin. To accomplish this, we have analyzed the per-protocol results from each trial, using standardized microbiological definitions. All studies reviewed reported adverse events, dropouts, and defaulters separately, facilitating our approach. However, we did not include these outcomes because they are not as well defined nor standardized, potentially creating greater between-study variability. As well, inter-study differences in providers and populations could have very important influences on these outcomes---even greater than any biologic differences in disease response. These would be balanced within each trial but could have created substantial bias with our analytic approach. If dropout, default, or side effects were associated with the same characteristics as failure or relapse, then excluding these outcomes could underestimate the poor outcomes associated with shorter rifampin exposures. But if not, then including these outcomes would simply reduce all differences between regimens.

This review had several limitations. First, we could identify few trials with direct head-to-head comparisons of rifampin duration, and even fewer directly comparing intermittent regimens. Hence, we had to pool results across studies; this increases potential confounding from differences in treatment, patients\' disease severity, or other differences in the study populations, since the studies were conducted in many different countries. The advantage of this approach is that we are able to include many more trials, thereby increasing the precision and avoiding selection bias [@pmed.1000146-Caldwell1]. However, the disadvantage is the greater potential for bias due to between-trial differences in participant characteristics, treatment regimens, as well as the differential impact of dropouts and other losses to follow-up [@pmed.1000146-Song1]. Concern about this latter problem should be alleviated by the consistent results from three analytic approaches---within the smaller set of trials with head-to-head comparisons, across all 57 trials, and the multivariate analysis. Also, the dispersion estimates from multivariable analysis suggest that treatment factors and underlying drug resistance accounted for almost all the differences in outcomes observed.

Most trials were initiated before 1980, limiting the number of participants with HIV infection and drug resistance. The lack of trials in HIV infected persons with active TB meant that the question of rifampin duration in treatment of HIV-TB could not be answered, due to insufficient power. This underscores the paucity of recent TB treatment trials and the urgent need for trials in drug resistant and/or HIV infected populations. There were no trials in children, reflecting a lack of rigorous trials in this population and the difficulties of microbiologic confirmation in this population. Death was not analyzed, because most TB-related deaths occur soon after diagnosis and are determined by comorbidity, age, severity of illness, and delay in diagnosis [@pmed.1000146-Greenaway1],[@pmed.1000146-Humphries1]. Deaths later in treatment are often from other causes [@pmed.1000146-Allan1],[@pmed.1000146-Davis1]. Hence, differences in the TB treatment regimen may have relatively little impact on mortality. We endeavored to minimize language bias by including studies published in French and Spanish as well as English. Interestingly, this yielded only three additional trials, or 5% of all trials included. In a recent review [@pmed.1000146-Ramos1], of all TB related papers listed in PubMed over 10 y, papers published in English, French, and Spanish represented 84% of all published literature worldwide. Hence, this review can be considered reasonably representative of publications in this field. However, in some fields, such as mental health, PubMed will fail to list a substantial proportion of relevant publications from low- to middle-income countries [@pmed.1000146-Kieling1], so we may have missed some important trials.

Finally, we were not able to distinguish between relapse of the same strain of *M. tuberculosis* that caused the initial infection and reinfection with a new strain of the bacillus. In settings with high rates of ongoing exposure to *M. tuberculosis*, particularly if HIV seroprevalence is also high, a relatively high proportion of cases of recurrent TB following initial apparent cure may be due to reinfection [@pmed.1000146-Sonnenberg1]. However, very few participants had HIV coinfection in the studies reviewed, and in studies with longer follow-up, the great majority of relapses occurred in the first 1--2 y, with very few occurring in the third to fifth years. This suggests that reinfection should have accounted for very few of the disease recurrences. Because follow-up was adequate in almost all studies---only four studies had less than 1-y follow-up---unequal follow-up should not have affected results---supported by the finding that duration of post-treatment follow-up was not associated with relapse rates in multivariable analysis.

Conclusion {#s4a}
----------

This review provides evidence against continued use of regimens that utilize rifampin for the first 2 mo only, as they are significantly and substantially inferior to regimens that use rifampin for at least 6 mo. This review also has identified an important need for adequately powered clinical trials that address dosing schedules, management of isoniazid mono-resistance, and the optimal duration of treatment to prevent relapse.
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